JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Francesca Barone, the Chief Scientific Officer of Candel Therapeutics , Inc. (NASDAQ:CADL), recently executed significant stock transactions according to a filing with the Securities and Exchange Commission. On March 18, Barone sold 32,146 shares of Candel Therapeutics common stock, totaling approximately $281,672. The shares were sold at a weighted average price of $8.7623, with individual sale prices ranging from $8.345 to $9.00. The transaction comes as CADL shares have shown remarkable strength, posting a 493% return over the past year and gaining 12% in the last week alone, according to InvestingPro data.
In addition to the sale, Barone exercised stock options to acquire 18,000 shares at a price of $1.55 per share, amounting to a total value of $27,900. Post-transaction, Barone holds 96,527 shares of common stock directly. These transactions were conducted under a 10b5-1 trading plan, which had been adopted on November 22, 2024. The company maintains a strong financial position with a healthy current ratio of 2.77 and more cash than debt on its balance sheet. Want deeper insights into insider trading patterns and 10+ additional ProTips? Discover more with InvestingPro.
In other recent news, Candel Therapeutics has made significant strides with its cancer treatment, CAN-2409. The company announced promising results from its Phase 3 study for prostate cancer, showing a notable improvement in disease-free survival. Additionally, the Phase 2 trial for pancreatic ductal adenocarcinoma demonstrated an impressive increase in median overall survival, highlighting the potential of CAN-2409 to extend patient lifespans significantly. These developments have led to strategic partnerships and analyst endorsements. Candel has teamed up with IDEA Pharma to enhance the commercial strategy for CAN-2409, particularly as it prepares for a Biologics License Application. Analysts at H.C. Wainwright and Citi have both maintained a Buy rating on the stock, with price targets set at $19 and $25, respectively. The analysts are optimistic about Candel’s ongoing trials for non-small cell lung cancer, with results anticipated soon. The company’s pipeline also includes CAN-3110, which is in early-stage trials for high-grade glioma. These recent advancements underscore Candel’s progress in the field of cancer immunotherapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.